Premenstrual Syndrome (PMS) Treatment Market Size and Forecast (2025–2033)

The Premenstrual Syndrome (PMS) Treatment Market is projected to grow from US$ 1,385.44 million in 2024 to US$ 1,909.67 million by 2033, expanding at a CAGR of 3.63% during the forecast period from 2025 to 2033. Growth is being driven by rising awareness of women’s health, increasing incidence of PMS symptoms, advances in hormonal and non-hormonal therapies, and the global expansion of healthcare accessibility for women.

Premenstrual Syndrome Treatment Market Outlook

Premenstrual Syndrome (PMS) refers to a group of physical, emotional, and behavioral symptoms experienced by women during the luteal phase of their menstrual cycle. Treatments range from hormonal therapies such as oral contraceptives, to antidepressants (particularly selective serotonin reuptake inhibitors or SSRIs), nonsteroidal anti-inflammatory drugs (NSAIDs), diuretics, and lifestyle modifications including exercise, nutrition, and stress management.

Globally, the PMS treatment market is expanding as awareness of reproductive health increases and the effects of PMS on productivity and daily life become more recognized. There is a notable rise in demand for earlier diagnosis and personalized care approaches. Moreover, the availability of over-the-counter supplements, vitamins, and herbal therapies further supports the market’s growth trajectory.

Improved access to gynecological services, continued research on hormonal regulation, and growing acceptance of women’s health topics are creating favorable conditions for market expansion. With increasing demand for effective symptom management, PMS treatment continues to be a critical component of modern women’s healthcare worldwide.

Drivers of Growth in the Premenstrual Syndrome Treatment Market

Increased Awareness and Education on Women’s Health

One of the major drivers of the PMS treatment market is growing global awareness about women’s health. Educational campaigns, social media movements, and government-led wellness programs are helping women better understand PMS and available treatment options. Early diagnosis and professional consultation have become more common, improving treatment adoption rates.

According to the National Institutes of Health (NIH), approximately 75% of women experience some symptoms of PMS, with around 5% suffering from severe cases known as Premenstrual Dysphoric Disorder (PMDD). This growing awareness is pushing more women to seek professional medical treatment, driving global market demand for both pharmaceutical and non-pharmaceutical therapies.

Pharmaceutical and Non-Pharmaceutical Treatment Advances

Technological and pharmacological progress has strengthened the PMS treatment market. Hormonal therapies, antidepressants (particularly SSRIs), NSAIDs, and nutritional supplements continue to evolve with enhanced efficacy and safety profiles.

For example, in September 2023, Vistagen, a clinical-stage biopharmaceutical company, reported promising data from a Phase 2A study of PH80, a nasal spray for treating PMDD symptoms including mood disturbances, pain, and behavioral changes.

Meanwhile, the growing adoption of herbal and lifestyle-based therapies—such as vitamin B6, magnesium supplements, mindfulness, and yoga—offers diverse options for women seeking alternative or complementary approaches. The availability of multiple therapeutic paths promotes personalization of treatment, enhancing patient satisfaction and long-term adherence.

Increasing Healthcare Access and Urbanization

Rapid urbanization and better healthcare infrastructure, especially in developing economies, are significantly improving access to PMS treatment. Urban women are more exposed to awareness campaigns, medical centers, and pharmacies offering both prescription and non-prescription therapies.

Insurance coverage, telemedicine services, and online pharmacy platforms are also expanding access, allowing women to consult professionals conveniently. This combination of healthcare modernization and accessibility supports robust growth of the PMS treatment market globally.

Request a free sample copy of the report

Challenges in the Premenstrual Syndrome Treatment Market

Limited Diagnosis and Awareness in Developing Regions

Despite global progress, PMS remains underdiagnosed in many regions, particularly in rural and low-income areas. Cultural taboos, lack of awareness, and inadequate access to gynecological care hinder diagnosis and treatment uptake.

These limitations restrict the market’s reach and potential. Furthermore, healthcare infrastructure deficiencies and low spending power in developing economies constrain companies from introducing advanced PMS therapies widely.

Side Effects and Compliance Issues with Treatment Options

Pharmaceutical options, including SSRIs, hormonal contraceptives, and NSAIDs, often carry side effects such as weight gain, nausea, headaches, or mood swings. These adverse effects can reduce adherence and compromise treatment outcomes.

Since PMS is a recurring condition, long-term compliance is essential. Poor adherence results in suboptimal outcomes, reducing the effectiveness of available therapies. Non-pharmaceutical approaches, while generally safer, may not provide adequate relief for severe symptoms, highlighting the need for improved, better-tolerated treatments.

Market Segments

Analgesics in Premenstrual Syndrome Treatment Market

Analgesics remain a cornerstone of PMS treatment for managing pain, cramps, and headaches. NSAIDs such as ibuprofen and naproxen are widely used over-the-counter medications for mild to moderate symptoms. Their accessibility, affordability, and rapid relief make them highly popular. Pharmaceutical companies continue to expand their retail and e-commerce distribution networks, further boosting segment growth.

Prescription Premenstrual Syndrome Treatment Market

The prescription segment is driven by hormonal therapies, SSRIs, and diuretics used to treat severe PMS or PMDD. Healthcare professionals recommend these for patients experiencing significant mood or physical disruptions. Increased awareness of PMDD and the expansion of women’s health clinics globally are strengthening demand for prescription treatments.

Innovation in novel oral contraceptives and safer antidepressants continues to support this segment. In March 2024, Pfizer Inc. launched Loryna, a new oral therapy for PMDD, approved by the U.S. FDA, marking an important advancement in women’s mental health treatment.

Premenstrual Syndrome Hospital Pharmacies Market

Hospital pharmacies are key distribution centers for prescription PMS medications, especially for patients needing clinical assessments. Women consulting gynecologists in hospitals often receive direct prescriptions, ensuring continuity of care.

This segment benefits from the increasing establishment of hospital-based gynecology departments, rising awareness of PMDD, and the availability of advanced medicines. Hospitals also provide diagnostic and therapeutic support for severe cases, contributing to steady market expansion.

Regional Insights

United States

The United States dominates the global PMS treatment market due to its advanced healthcare infrastructure, high awareness levels, and broad availability of both prescription and OTC medications. Strong reimbursement systems, pharmaceutical innovation, and proactive health campaigns continue to propel growth. Rising PMDD diagnosis rates and tailored treatment solutions further reinforce the U.S. market’s leadership position.

France

France has one of the most developed women’s healthcare systems in Europe. The country’s PMS treatment market benefits from widespread access to gynecological services and government-supported wellness programs. Hospital and retail pharmacies play vital roles in dispensing therapies, and increasing awareness of PMDD is enhancing prescription drug usage.

China

China’s PMS treatment market is expanding rapidly, driven by urbanization, growing health literacy, and greater access to women’s healthcare services. Over-the-counter analgesics and traditional herbal remedies dominate the market, but prescription treatments are gaining traction in major cities. Rising disposable incomes and government efforts to promote women’s health ensure long-term market growth.

Brazil

Brazil is experiencing growing awareness about women’s reproductive health, particularly in urban areas. Pharmacies remain the primary distribution channel for PMS drugs, including analgesics and hormonal therapies. Government initiatives, private health education programs, and the rise of telemedicine are improving accessibility, even in rural regions.

Saudi Arabia

Saudi Arabia’s PMS treatment market is supported by Vision 2030, which emphasizes healthcare modernization and women’s health empowerment. Increased awareness campaigns, rising disposable income, and cultural openness are driving growth. Hospital pharmacies lead the prescription drug segment, while retail and online platforms provide widespread access to over-the-counter medications and supplements.

Market Segmentation

By Drug Type

·        Analgesics

·        Antidepressants

·        Oral Contraceptives and Ovarian Suppression Agents

·        Others

By Type

·        Prescription

·        Over-the-Counter

By Distribution Channel

·        Hospital Pharmacies

·        Drug Stores and Retail Pharmacies

·        Online Stores

By Country

North America: United States, Canada
Europe: France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey
Asia Pacific: China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand
Latin America: Brazil, Mexico, Argentina
Middle East & Africa: Saudi Arabia, UAE, South Africa

Key Players

·        AbbVie Inc.

·        BASF SE

·        Bayer AG

·        Dr. Reddy’s Laboratories Ltd.

·        Eli Lilly and Company

·        GlaxoSmithKline Plc.

·        H. Lundbeck A/S

·        Pfizer Inc.

·        SHIONOGI & Co. Ltd.

Market Outlook (2025–2033)

The PMS treatment market will continue its upward trajectory, increasing from US$ 1,385.44 million in 2024 to US$ 1,909.67 million by 2033 at a CAGR of 3.63%. The expansion will be supported by improved diagnosis, growing healthcare access, and continuous pharmaceutical innovation.

Rising investment in women’s health research, digital health adoption, and expanding telemedicine platforms are also expected to improve treatment availability and compliance. Meanwhile, the integration of personalized medicine and emerging drug delivery systems will help improve therapeutic outcomes and patient satisfaction.

Conclusion

The global Premenstrual Syndrome (PMS) Treatment Market is set for steady growth over the next decade, underpinned by heightened health awareness, technological innovation, and improved access to care. As cultural stigmas around women’s reproductive health continue to decline, demand for PMS therapies—both pharmaceutical and non-pharmaceutical—will expand significantly.

North America and Europe will maintain market dominance through innovation and robust healthcare systems, while Asia-Pacific and the Middle East show strong potential due to rising urbanization and policy support. The continued introduction of safer, more effective therapies positions the PMS treatment market as a vital and evolving segment of women’s healthcare worldwide.